Cannabichromene (CBC) is one of the major cannabinoids found within Cannabis sativa alongside tetrahydrolcannabinol (THC) and cannabidiol (CBD). CBC is derived from naturally occurring cannabigerolic acid, produced by the Cannabis plant as a precursor to these major cannabinoids. CBC is a non-psychoactive cannabinoid that differs in interaction with the endocannabinoid system from THC and CBD by exhibiting poor binding ability with the CB1 and CB2 receptors in the brain. CBC is showing promise in certain medical treatments and exhibits benefits as a stand-alone cannabinoid and also in conjunction with other cannabinoids.

Of these potential benefits, CBC shows potential in anti-inflammatory properties through its ability to bind with transient receptor potential channels of both the vanilloid type-1 (TRPV1) receptor and ankyrin type-1 receptor (TRPA1). These receptors are linked to pain perception and upon activation increase endocannabinoids within the body to assist in anti-inflammatory response. [1] CBC has also been shown to act on pain in a different manner than common non-steroidal anti-inflammatory drugs while exhibiting none of the side effects of these over the counter medications. [2]

In addition to the anti-inflammatory potential CBC exhibits on its own, it appears that when combined with other cannabinoids this potential may be increased. One study has shown that when CBC is combined with THC, anti-inflammatory capabilities may increase. [3] A process known as the entourage effect enables these two cannabinoids to work together to display far more anti-inflammatory abilities than either compound possess individually.

References

  1. Maione, Sabatino, et al. Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. Br J Pharmacol. October 2010. Journal Impact Factor = 6.81. Times Cited = 44
  2. Izzo, AA, et al. Inhibitory effect of cannabichromeme, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br J Pharmacol. June 2012. Journal Impact Factor = 6.81. Times Cited = 22
  3. Delong, Gerald T., et al. Pharmacological Evaluation of the Natural Constituent of Cannabis Sativa, Cannabichromene and its Modulation by Delta-9 Tetrahydrocannabinol. Drug Alcohol Depend. Nov 2010.